- Thinly traded Prana Biotechnology (PRAN +44%) continues its up move on an impressive 29x surge in volume. Shares have rallied almost 70% since trading resumed Tuesday.
- No particular news accounts for the action. It recently reported meeting with European regulators to clarify a path to a Phase 3 clinical trial for lead product candidate PBT2. It appears that it will need to conduct additional preclinical testing to assess safety issues before getting clearance to start human studies.
- Previously: Prana Biotech not quite there for start of European late-stage study of lead product candidate in Huntington's (Dec. 23, 2016)
Prana Bio shows some life; shares up 44%
Recommended For You
About ATHE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ATHE | - | - |
Alterity Therapeutics Limited |